Healthcare ❯ Pharmaceuticals ❯ Drug Development

GLP-1 Drugs

Eli Lilly Market Competition Ozempic Orforglipron Novo Nordisk Mounjaro and Zepbound Mounjaro

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

Management says the purchases are a long-term hedge funded by strong GLP-1 profits that will not meaningfully change near-term earnings.

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

Novo Nordisk Slumps on Weak 2026 Outlook as GLP-1 Pill Uptake Builds

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Berenberg Upgrades Novo Nordisk to Buy, Sets DKK425 Price Target